Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies

To date, the RV144 HIV vaccine trial has been the only study to show that immunization can confer protection from HIV infection. While encouraging, the modest 31.2% (P = 0.04) efficacy achieved in this study left significant room for improvement, and created an incentive to optimize the AIDSVAX B/E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Doran, Rachel C., Tatsuno, Gwen P., O’Rourke, Sara M., Yu, Bin, Alexander, David L., Mesa, Kathryn A., Berman, Phillip W.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916523/
https://ncbi.nlm.nih.gov/pubmed/29689099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0196370
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados